The defense industry has had the same names at the top for decades. Lockheed Martin. Northrop Grumman. Raytheon. General Dynamics. These slow-moving contracting giants were designed for a different century.
Enter Anduril Industries, which is quickly building a strong case to displace entrenched government contractors —while doing things faster than anyone thought possible.
Founded in 2017 by Palmer Luckey, the creator of Oculus VR, Anduril has grown from a defense-tech startup to generating $2 billion in annual revenue in 2025, with a $20 billion Army contract awarded in March and a new funding round reportedly in progress at a $60 billion valuation.
Founder and CEO Palmer Luckey has stated plainly that the company “will definitely” go public, noting there is not “really a path” to winning the kind of trillion-dollar defense contracts the company is pursuing without doing so.The only question is when.
Here’s what interested pre-IPO or IPO investors need to know to be prepared.
Anduril Industries IPO Timeline and Valuation
This is not a typical defense contractor story. The defense-tech startup occupies a rare niche with only one other entrant, Palantir, which has already gone public. Namely, Anduril is a software company that builds weapons, and that distinction is why investors, the Pentagon, and the broader market are paying attention.
In June 2025, Anduril closed a $2.5 billion Series G at a $30.5 billion valuation, more than doubling its prior $14 billion mark from August 2024. Then, in March 2026, it was reported to be raising another $4 billion round at a $60 billion valuation, led by Andreessen Horowitz and Thrive Capital.
At $4.3 billion in projected 2026 revenue, that valuation implies approximately 14 times forward revenue, an aggressive multiple for a traditional defense contractor. But reasonable, perhaps even modest, for a high-growth software platform with a dominant position in the growing defense procurement sector.
As for timing, Luckey has signalled hewants to list after demonstrating that Arsenal-1 can deliver at scale, which points to a 2026 or 2027 window, contingent on the Ohio facility coming online as planned. Forge Global places the probability of a 2026 listing atapproximately 60%. No filing date has been confirmed.
3 Key Takeaways for Interested Pre-IPO Investors
1. The $20 billion Army contract represents a significant milestone that may substantially impact the company's trajectory.
A 10-year enterprise vehicle worth up to $20 billion — covering Anduril’s full commercial outlay through 2036 — is not just a project win. This is a foundational relationship with the world's largest defense buyer. For a pre-IPO company, that kind of contract is unusual and may help reduce certain revenue-related risks relative to earlier-stage private companies. It does not eliminate execution risk, it may impact how investors evaluate the company.
2. Arsenal-1 is the IPO trigger and biggest near-term risk.
The Ohio manufacturing facility is the linch pin of Anduril’s transition from a high-growth startup to a scaled defense manufacturer. Luckey has explicitly tied the IPO timing to proving Arsenal-1can deliver, which means the July 2026 production launch date functions as a leading indicator for both the business and the listing. Investors watching this company should watch that milestone first. A successful on-time launch could help validate the revenue trajectory and likely accelerate IPO timing. Conversely, delays could impact these timelines.
3. This is a software company that makes hardware.
The drones and autonomous vehicles get the headlines, but Lattice OS is the moat. Because Lattice is the integration layer for every system Anduril builds, it’s designed as an open platform for integrating third-party hardware. Simply put, it’s sticky in a way hardware alone isn't. Every new Anduril customer deepens the Lattice network. Every new contract makes the platform more valuable. This matters when evaluating the company’s long-term competitive position and the durability of its margins.
The Pros and Cons of Pre-IPO Exposure
Pre-IPO access to Anduril shares exists today through secondary market platforms and structured vehicles, but investors should be open-eyed about the trade-offs:
● Illiquidity: Pre-IPO positions cannot be freely sold. Capital is locked until a liquidity event — whether an IPO, an acquisition, or a secondary transaction —occurs.
● No timeline: No filing date has been set. A slip in Arsenal-1’s production schedule, a shift in conditions, or a change in priorities could push the listing into 2027 or beyond.
● Valuation reset risk: At $60 billion, Anduril is priced for strong execution. A missed revenue milestone, a contract dispute, or a shift in defense budgets could compress the valuation before a listing occurs.
● Key-person risk: Anduril’s culture, product vision, and government relationships are closely tied to Palmer Luckey. His continued involvement is a meaningful factor in the company’s trajectory.
● Access restrictions: Pre-IPO investment in Anduril is generally limited to qualified purchasers. These restrictions reflect the complexity and risk profile involved.
The Right Way to Assess Pre-IPO Opportunities
Pre-IPO investing in companies like Anduril is not suitable for all investors. But for those with an appropriate risk tolerance, long time horizon, and the right portfolio context, pre-IPOs like Anduril may provide access to private valuation before public trading begins.
Access to pre-IPO companies like Anduril requires more than a brokerage account. It requires the right relationships, diligence, infrastructure, and investment structures to evaluate and enter these positions responsibly.
HUDSONPOINT capital provides clients with access to private-market opportunities typically unavailable to individual investors. Our approach includes:
● Rigorous screening and due diligence on every opportunity we present
● Pooled investment structures designed to help provide access to certain private market allocations.
● Portfolio design strategies that seek to consider risk factors and how a pre-IPO position may interact with your existing holdings
● Clear education and transparency around the specific risks of private securities
If you're interested in understanding whether pre-IPO exposure to Anduril or other high-profile private companies fits your portfolio, we can help you explore potential access to available opportunities through appropriate investment structures.
The opinions expressed are those of HUDSONPOINT capital and not those of Arete Wealth.
Please note that any investment involves risk including loss of principal. This is for informational and educational purposes only and should not be construed as investment advice or an offer or solicitation of any products or services. Opinions are subject to change with market conditions. The views and strategies may not be suitable for all investors and are not intended to be relied on for legal or tax advice.
Securities offered through Arete Wealth Management, LLC, members FINRA and SIPC. Investment advisory services offered through Arete Wealth Advisors, LLC an SEC registered investment advisory firm.
.png)
.png)
